Starpharma Holdings’ Shares Nosedive Around 29% After US FDA Request Further Data For VivaGel® BV Approval

  • Dec 27, 2018 AEDT
  • Team Kalkine
Starpharma Holdings’ Shares Nosedive Around 29% After US FDA Request Further Data For VivaGel® BV Approval

Leading developer of dendrimer products Starpharma Holdings Limited (ASX: SPL) shares went down by 29.643 percent on 27 December 2018 after US Food and Drug Administration (FDA) requested confirmatory clinical data for the approval VivaGel® BV which is used for the  treatment of bacterial vaginosis (BV) and the prevention of recurrent BV (rBV).

Starpharma is requesting a meeting with the FDA to discuss the data requirement, and it is very keen to secure approval as soon as possible. The company is going to discuss its next steps with its US partner, ITF Pharma, and any potential impact on its US license.

As of now, FDA has not identified any approvability issues in relation to the safety, manufacturing or quality of VivaGel® BV which is very encouraging for the company. In their advice, FDA has also acknowledged the demonstrated efficacy benefits of VivaGel® BV although they have requested confirmatory data before approval.

The CEO of Dr. Jackie Fairley said that the management of the company is very surprised and extremely disappointed with the US FDA's requirement for confirmatory data for the approval of VivaGel® BV considering the complex nature of the data provided. However, the company is greatly encouraged by the FDA’s acknowledgment of the significant unmet medical need that would be fulfilled by VivaGel®, and they have expressed a desire to work with Starpharma to secure approval to make VivaGel® BV available to women in the US as soon as possible.

Starpharma’s breakthrough product VivaGel® BV is already approved in the EU and Australia and the company is in the middle of regulatory processes for this product in other markets also which are entirely independent of FDA approval.  The company has informed that the initial launches for VivaGel® BV will go forward as planned in various Mundipharma regions (including Europe) and Australia during the 1H 2019.

Aside from VivaGel® BV, the company is also going to continue to commercially exploit its broad portfolio of DEP® drugs which include DEP® docetaxel, DEP® irinotecan, DEP® cabazitaxel, and a range of other internal and partnered programs which include the novel oncology agent AZD0466, which is being developed under license by AstraZeneca.

Recently, Starpharma and ITF Pharma signed a license for the sales and marketing rights of its innovative product VivaGel® BV in the U.S. As per the terms of the License deal, besides receiving attractive tiered royalties on sales, Starpharma will also receive around AUD$142 million in regulatory approval and commercialization milestones. Initially, Starpharma will be the sole supplier of the VivaGel® BV to ITF Pharma, however, in the future, Italfarmaco may set up its own manufacturing unit after receiving the necessary approvals from US Food and Drug Administration.

In the last six months, the share price of the company decreased by 23.89 percent as on 24 December 2018.  SPL’s shares traded at $0.985 with a market capitalization of circa $520.27 million as on 27 December 2018 (AEST 4:00 PM).


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK